Stock Price & Analysis

MYO stock closed at $5.38 on March 21, 2025, with a slight decline of -0.74%. Considering the upcoming earnings report and current market sentiment, it may be prudent to hold or consider selling MYO stock at this time.

MYO stock is predicted to reach a target price of $6.20 by the end of 2025, driven by potential positive earnings and market growth. If the upcoming earnings report on March 10, 2025, is strong, the stock could see an uptrend. Conversely, a disappointing report may lead to a price drop to around $4.80.

The S1 support level for MYO Stock is $4.7 ,The R1 resistant level for MYO Stock is $5.5.

As of the end of day on 2025-04-02, the price of MYO Stock was $4.996.

The target price for MYO Stock according to analyst rating is 8.81, with the highest price target at 11.00 and the lowest at 6.75. Analysts have a Strong Buy rating on MYO Stock overall.

The market cap of MYO is $168.5M.

MYO appears overvalued due to high valuation multiples and lack of profitability. The EV/EBITDA ratio of 8.64 indicates a premium. Recent earnings and a public offering have caused slight stock drops, showing investor caution. Insider buying is positive, but institutional movements are mixed. Without strong earnings growth, MYO's valuation seems stretched.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteran’s administration, and others.

MYO stock is predicted to reach $15 by 2030, driven by strong earnings growth and expanding market share in the medical device industry. The stock's recent insider buying activity and positive institutional sentiment further support this bullish outlook.

MYO has a total of 101 employees.